Showing 2211-2220 of 5643 results for "".
- Kodiak Reboots Tarcocimab Tedromer Development Program Following Strong Positive Phase 3 DR Resultshttps://modernod.com/news/kodiak-reboots-tarcocimab-tedromer-development-program-following-strong-positive-phase-3-diabetic-retinopathy-results/2481948/Three months after deciding to discontinue tarcocimab tedromer due to two failed late-stage trials, Kodiak Sciences announced it is rebooting its clinical program after its phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to sev
- GALE Extension Study Shows Syfovre Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with GAhttps://modernod.com/news/gale-extension-study-shows-syfovre-continued-to-demonstrate-increasing-treatment-effects-over-3-years-in-patients-with-ga/2481943/Apellis Pharmaceuticals announced data from the GALE extension study following 3 years of continuous treatment with Syfovre (pegcetacoplan injection), the first FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data were rep
- Pantheon Vision Raises $2.5 Million in Seed Funding to Launch Development of Bioengineered Corneal Implanthttps://modernod.com/news/pantheon-vision-raises-25-million-in-seed-funding-to-launch-development-of-bioengineered-corneal-implant/2481936/Pantheon Vision has announced $2.5 million in seed financing from Baltimore-based KeraLink International (KLI), a non-profit organization singularly focused on eradicating corneal blindness with an emphasis on low- and middle-income countries. The funding will be us
- AffaMed Therapeutics Announces Positive Topline Results from Real-World Study in China Evaluating Dextenza in Patients after Cataract Surgeryhttps://modernod.com/news/affamed-therapeutics-announces-positive-topline-results-from-real-world-study-in-china-evaluating-dextenza-in-patients-after-cataract-surgery/2481932/AffaMed Therapeutics announced positive topline results from the real-world study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain followi
- AbbVie Enters into Option Agreement with Aldeyra Therapeutics for License to Develop and Commercialize Reproxalaphttps://modernod.com/news/abbvie-enters-into-option-agreement-with-aldeyra-therapeutics-for-license-to-develop-and-commercialize-reproxalap/2481929/Aldeyra Therapeutics announced that it has entered into an exclusive option agreement with AbbVie in which AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in the US, and an exclusive license to develop, manufacture, and comme
- SpyGlass Pharma Initiates Phase 1/2 Clinical Trial of its Intraocular Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-initiates-phase-12-clinical-trial-of-its-intraocular-drug-delivery-platform/2481924/SpyGlass Pharma announced the initiation of a phase 12 clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts. The SpyGlass
- Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophyhttps://modernod.com/news/annexon-receives-prime-designation-from-the-ema-for-anx007-for-the-treatment-of-geographic-atrophy/2481911/Annexon announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The EMA granted this designation based on the phase 2 ARCHER
- SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Diseasehttps://modernod.com/news/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/2481894/SpliceBio has announced the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. Under the terms of
- Zeiss and Boehringer Ingelheim Partner to Develop Early Detection of Eye Diseases and Prevent Vision Losshttps://modernod.com/news/zeiss-and-boehringer-ingelheim-partner-to-develop-early-detection-of-eye-diseases-and-prevent-vision-loss/2481859/Zeiss Medical Technology and Boehringer Ingelheim announced a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with eye diseases. The partnership aims to bring togeth
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT